Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51
Preprint
Abstract
Background: Homologous recombination deficiency (HRD) in ovarian cancer confers increased sensitivity to Poly-ADP-Ribose-Polymerase (PARP) inhibitors and platinum. The homologous recombination (HR) mediator RAD51, however, is commonly overexpressed, potentially driving unregulated HR. Due to non-quantitative measurements and heterogeneous cohorts, the clinical relevance of RAD51 expression in ovarian cancer is unclear. Methods: Fluorescent immunohistochemistry and multispectral imaging were used to quantitate RAD51 expression, in relation to other markers, in independent cohorts of ovarian carcinomas from British Columbia Cancer (BCC n =284) and the phase III SCOTROC4 trial ( n =268). Independent cohorts (TCGA n =566, GSE9891 n =267, GSE26712 n =185 and GSE3149 n =146) were used for mRNA expression and immune infiltration analyses. Results: RAD51-High tumours had shorter progression-free and overall survival compared to RAD51-Low cases in both BCC and SCOTROC4. The negative prognostic significance of high RAD51 was primarily evident in cases classified “HRD negative” by the Myriad genomic scar assay. Unexpectedly, overexpression of RAD51 in ovarian cancer cell lines did not affect sensitivity to platinum or PARP inhibitors, but modified the expression of immune-regulatory genes. Accordingly, tumours with high RAD51 mRNA showed consistent changes in immunomodulatory transcripts across four independent ovarian cancer cohorts. In-situ multiplexed imaging confirmed that high RAD51 tumours correlated with tumour exclusion of cytotoxic-T-cells, possibly explaining their poor outcomes after chemotherapy. Conclusions: High RAD51 expression, in conjunction with a HRD score nd line maintenance treatment of ovarian cancer. Our findings suggest that HRD negative ovarian tumours may be further stratified by RAD51 expression status in the context of platinum sensitivity, and may serve to guide future trials of HRD targeted agents.Keywords
All Related Versions
- Published version: EMBO Molecular Medicine, 13 (5), e13366.
This publication has 55 references indexed in Scilit:
- Homologous Recombination and the Formation of Complex Genomic RearrangementsTrends in Cell Biology, 2019
- Homologous recombination and the repair of DNA double-strand breaksJournal of Biological Chemistry, 2018
- PARP inhibitors: Synthetic lethality in the clinicScience, 2017
- Repair of Strand Breaks by Homologous RecombinationCold Spring Harbor Perspectives in Biology, 2013
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsMolecular Oncology, 2011
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Rad51 overexpression promotes alternative double-strand break repair pathways and genome instabilityOncogene, 2004
- Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiationNucleic Acids Research, 1998
- Hyper-recombination and Bloom's syndrome: microbes again provide clues about cancer.Genome Research, 1995